Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease

Expert Review of Neurotherapeutics

Volumn 14, Issue 9, 2014, Pages 973-986

  Panza, Francesco ^a,b   Solfrizzi, Vincenzo ^a   Imbimbo, Bruno P ^c   Giannini, Michele ^a   Santamato, Andrea ^d   Seripa, Davide ^b   Logroscino, Giancarlo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c Research and Development Department   (Italy)

^d UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Alzheimer's disease; cognitive disorder; dementia; gantenerumab; monoclonal antibody; passive immunotherapy; solanezumab

Indexed keywords

GANTENERUMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; BLOOD BRAIN BARRIER; BRAIN SIZE; CLINICAL DEMENTIA RATING; DRUG BINDING SITE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOTHERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; REVIEW; SURFACE PLASMON RESONANCE; CLINICAL TRIAL (TOPIC); TREATMENT OUTCOME;

ALZHEIMER DISEASE; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; TREATMENT OUTCOME;

EID: 84906667638     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2014.945522     Document Type: Review

References (84)

1. Schneider LS, Mangialasche F, Andreasen N, et al. Clinical trials. and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med 2014;275(3):251-83
2. Thies W, Bleiler L; Alzheimer's Association. 2013 Alzheimer's disease facts and figures. Alzheimers Dement 2013;9(2):208-45
3. Walter J, Kaether C, Steiner H, Haass C. The cell biology of Alzheimer's disease: uncovering the secrets of secretases. Curr Opin Neurobiol 2011;11(5):585-90
4. Panza F, Logroscino G, Imbimbo BP, Solfrizzi V. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease? Curr Opin Psychiatry 2014;27(2):128-37
5. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7(3):280-92
6. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7(3):270-9
7. Sperling RA, Karlawish J, Johnson KA. Preclinical Alzheimer disease-the challenges ahead. Nat Rev Neurol 2013;9(1):54-8
8. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367(9):795-804
9. Villemagne VL, Burnham S, Bourgeat P, et al. Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid b deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013;12(4):357-67
10. Desikan RS, McEvoy LK, Thompson WK, et al. Amyloid-b-associated clinical decline occurs only in the presence of elevated Ptau. Arch Neurol 2012;69(6):709-13
11. Knopman DS, Jack CR Jr, Wiste HJ, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012;78(20):1576-82
12. Jack CR Jr, Knopman DS, Weigand SD, et al. An operational approach to NIA-AA criteria for preclinical Alzheimer's disease. Ann Neurol 2012;71(6):765-75
13. Knopman DS, Jack CR Jr, Wiste HJ, et al. Brain injury biomarkers are not dependent on b-amyloid in normal elderly. Ann Neurol 2013;73(4):472-80
14. Panza F, Solfrizzi V, Imbimbo BP, et al. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. Expert Rev Clin Immunol 2014;10(3):405-19
15. Sperling RA, Rentz DM, Johnson KA, et al. The A4 Study: stopping AD before symptoms begin? Sci Transl Med 2014; 6(228):228fs13
16. Eli Lilly and Company with Alzheimer's disease cooperative study (ADCS). Clinical trial of solanezumab for older individuals who may be at risk for memory loss (A4). ClinicalTrials.gov NCT02008357 Available from: http://clinicaltrials.gov/ct2/show/NCT02008357?term=Anti-Amyloid +Treatment+in+Asymptomatic+AD&rank=1 [Last accessed 10 June 2014]
17. Mills SM, Mallmann J, Santacruz AM, et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol (Paris) 2013; 169(10):737-43
18. Washington University School of Medicine with Eli Lilly and Company, Hoffmann-La Roche, Alzheimer's Association, National Institute on Aging (NIA), and Avid Radiopharmaceuticals. Dominantly Inherited Alzheimer network trial: an opportunity to prevent dementia. A study of potential disease modifying treatments in individuals at risk for or with a type of early onset Alzheimer's disease caused by a genetic mutation. (DIAN TU). ClinicalTrials.gov NCT01760005 Available from: http://clinicaltrials.gov/ct2/show/NCT01760005?term= NCT01760005&rank=1 [Last accessed 10 June 2014]
19. Reiman EM, Langbaum JB, Fleisher AS, et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 2011;26(Suppl 3):321-9
20. Genentech and Banner Alzheimer's Institute. A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer disease, including a placebo-treated noncarrier cohort. ClinicalTrials.gov NCT01998841 Available from: http://clinicaltrials.gov/ct2/show/NCT01998841?term=NCT01998841&rank=1 [Last accessed 10 June 2014]
21. Lannfelt L, Relkin NR, Siemers ER. Amyloid-ß-directed immunotherapy for Alzheimer's disease. J Intern Med 2014; 275(3):284-95
22. Marciani DJ. New Th2 adjuvants for preventive and active immunotherapy of neurodegenerative proteinopathies. Drug Discov Today 2014; Epub ahead of print
23. Lemere CA. Immunotherapy for Alzheimer's disease: hoops and hurdles. Mol Neurodegener 2013;8:36
24. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid b-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6(8):916-19
25. Morgan D. Mechanisms of A beta plaque clearance following passive A beta immunization. Neurodegener Dis 2005; 2(5):261-6
26. Panza F, Frisardi V, Imbimbo BP, et al. Anti-b-amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab. Curr Alzheimer Res 2011;8(8):808-17
27. Imbimbo BP, Ottonello S, Frisardi V, et al. Solanezumab for the treatment of mild-to-moderate Alzheimer's disease. Expert Rev Clin Immunol 2012;8(2): 135-49
28. Tayeb HO, Murray ED, Price BH, Tarazi FI. Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive? Expert Opin Biol Ther 2013;13(7):1075-84
29. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370(4):322-33
30. Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370(4):311-21
31. Karran E, Hardy J. Antiamyloid therapy for Alzheimer's disease -are we on the right road? N Engl J Med 2014;370(4):377-8
32. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9(4):363-72
33. Blennow K, Zetterberg H, Rinne JO, et al. AAB-001 201/202 Investigators. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 2012;69(8):1002-10
34. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73(24): 2061-70
35. Sperling RA, Jack CR Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 2011;7(4): 367-85
36. Maia LF, Kaeser SA, Reichwald J, et al. Changes in amyloid-b and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci Transl Med 2013;5(194):194re2
37. Fagan AM, Xiong C, Jasielec MS, et al. Dominantly inherited Alzheimer network. longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med 2014;6(226):226ra30
38. Pfizer and JANSSEN Alzheimer immunotherapy research & development, LLC. Study evaluating the safety of AAB-003 (PF-05236812) in subjects with Alzheimer's disease. ClinicalTrials.gov NCT01193608 Available from: http://clinicaltrials.gov/ct2/show/NCT01193608?term=NCT01193608&rank=1 [Last accessed 10 June 2014]
39. Pfizer and JANSSEN Alzheimer immunotherapy research & development, LLC. Open label extension study evaluating safety and tolerability of AAB-003 (PF-05236812) in subject with mild to moderate Alzheimer's disease. ClinicalTrials. gov NCT01369225 Available from: http://clinicaltrials.gov/ct2/ show/NCT01369225?term=NCT01369225&rank=1 [Last accessed 10 June 2014]
40. Farlow M, Arnold SE, van Dyck CH, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement 2012;8(4):261-71
41. Siemers ER, Friedrich S, Dean RA, et al. Safety and changes in plasma and cerebrospinal fluid amyloid-beta after a single administration of an amyloid-beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 2010;33(2):67-73
42. Eli Lilly and Company. Continued safety monitoring of solanezumab in Alzheimer's disease (EXPEDITION EXT). ClinicalTrials.gov NCT01127633 http://clinicaltrials.gov/ct2/show/NCT01127633?term=NCT00905372&rank=2 [Last accessed 10 June 2014]
43. Eli Lilly and Company. Progress of mild Alzheimer's disease in participants on solanezumab versus placebo (EXPEDITION3). ClinicalTrials.gov NCT01900665 Available from: http://clinicaltrials.gov/ct2/show/NCT01900665?term= NCT01900665&rank=1 [Last accessed 18 May 2014]
44. Moreth J, Mavoungou C, Schindowski K. Passive anti-amyloid immunotherapy in Alzheimer's disease: what are the most promising targets? Immun Ageing 2013; 10(1):18
45. Delrieu J, Ousset PJ, Vellas B. Gantenerumab for the treatment of Alzheimer's disease. Expert Opin Biol Ther 2012;12(8):1077-86
46. Novakovic D, Feligioni M, Scaccianoce S, et al. Profile of gantenerumab and its potential in the treatment of Alzheimer's disease. Drug Des Devel Ther 2013;7: 1359-64
47. Lemere CA, Lopera F, Kosik KS, et al. The E280A presenilin 1 Alzheimer mutation produces increased Ab42 deposition and severe cerebellar pathology. Nat Med 1996; 2(10):1146-50
48. Lopera F, Ardilla A, Martinez A, et al. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA 1997; 277(10):793-9
49. Caselli RJ, Reiman EM. Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention. J Alzheimers Dis 2013; 33(Suppl 1):S405-16
50. Adolfsson O, Pihlgren M, Toni N, et al. An effector-reduced anti-b-amyloid (Ab) antibody with unique Ab binding properties promotes neuropotection and glial engulfment of Ab. J Neurosci 2012;32(28): 9677-89
51. Genentech. A study to evaluate the efficacy and safety of MABT5102A in patients with mild to moderate Alzheimer's disease (ABBY). ClinicalTrials.gov NCT01343966 Available from: http://clinicaltrials.gov/ct2/show/NCT01343966?term= NCT01343966&rank=1 [Last accessed 10 June 2014]
52. Genentech. A study to evaluate the impact of MABT5102A on brain amyloid load and related biomarkers in patients with mild to moderate Alzheimer's disease. ClinicalTrials. gov NCT01397578 Available from: http://clinicaltrials. gov/ct2/show/NCT01397578?term=MABT5102A&rank=3 [Last accessed 10 June 2014]
53. Genentech. A long-term safety extension study of studies ABE4869g and ABE4955g in patients with mild to moderate Alzheimer's disease treated with crenezumab. ClinicalTrials.gov NCT01723826 Available from: http:// clinicaltrials.gov/ct2/show/NCT01723826?term=NCT01723826&rank=1 [Last accessed 10 June 2014]
54. Eisai Inc. A randomized, double-blind, placebo-controlled, combined single ascending dose and multiple ascending dose study. ClinicalTrials.gov identifier NCT01230853 Available from: http://clinicaltrials.gov/ct2/show/ NCT01230853?term=NCT01230853&rank=1 [Last accessed 10 June 2014]
55. Eisai Inc. A study to evaluate safety, tolerability, and efficacy of BAN2401 in subjects with early Alzheimer's disease. ClinicalTrials.gov identifier NCT01767311 Available from: http://clinicaltrials.gov/ct2/show/ NCT01900665?term=NCT01900665&rank=1 [Last accessed 10 June 2014]
56. Pul R, Dodel R, Stangel M. Antibody-based therapy in Alzheimer's disease. Expert Opin Biol Ther 2011;11(3):343-57
57. Loeffler DA. Intraveneous immunoglobulin and Alzheimer's disease: what now? J Neuroinflammation 2013;10(1):70
58. Dodel RC, Du Y, Depboylu C, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004;75(10):1472-4
59. Relkin N, Tsakanikas DI, Adamiak B, et al. A double blind, placebo-controlled, phase II clinical trial of intravenous immunoglobulin (IVIG) for treatment of Alzheimer's disease. Neurology 2008;70:A393
60. Dodel R, Rominger A, Bartenstein P, et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 2013;12(3):233-43
61. Baxter Healthcare Corporation. A phase 3 study evaluating safety and effectiveness of immune globulin intravenous (IGIV 10%) for the treatment of mild-to-moderate Alzheimer's disease. ClinicalTrials.gov NCT00818662 Available from: http://clinicaltrials.gov/ct2/show/NCT00818662?term=NCT00818662&rank=1 [Last accessed 10 June 2014]
62. Sutter Health. Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment (MCI). ClinicalTrials.gov NCT01300728 Available from: http://clinicaltrials.gov/ct2/show/NCT01300728?term=NCT01300728&rank=1 [Last accessed 10 June 2014]
63. Instituto Grifols SA. A study to evaluate albumin and immunoglobulin in Alzheimer's disease (AMBAR). ClinicalTrials.gov NCT01561053 Available from: http://clinicaltrials.gov/ct2/show/NCT01561053?term=NCT01561053&rank=1 [Last accessed 10 June 2014]
64. Rauchenberger R, Borges E, Thomassen-Wolf E, et al. Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor3. J Biol Chem 2003;278(40):38194-205
65. Steidl S, Ratsch O, Brocks B, et al. In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification. Mol Immunol 2008;46(1):135-44
66. Bohrmann B, Baumann K, Benz J, et al. Gantenerumab: a novel human anti-Ab antibody demonstrating sustained cerebral amyloid-b binding and elicits cell-mediated removal of human amyloid-b. J Alzheimers Dis 2012;28(1):49-69
67. Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 2012;69(2): 198-207
68. Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003;9(4):448-52
69. Boche D, Zotova E, Weller RO, et al. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 2008;131(Pt 12):3299-310
70. Koenigsknecht-Talboo J, Meyer-Luehmann M, Parsadanian M, et al. Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J Neurosci 2008;28(52):14156-64
71. Seubert P, Khan K, Motter R, et al. Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP Mouse. Neurodegener Dis 2008; 5(2):65-71
72. DeMattos RB, Bales KR, Cummins DJ, et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001;98(15):8850-5
73. Hoffmann-La Roche F. A study of a high concentration liquid formulation versus a lyophilized formulation of gantenerumab in healthy volunteers. ClinicalTrials.gov NCT01636531 Available from: http://clinicaltrials.gov/ct2/ show/NCT01636531?term=gantenerumab&rank=5 [Last accessed 10 June 2014]
74. Chugai Pharmaceutical. A multiple-dose study of gantenerumab in Japanese Alzheimer's disease patients. ClinicalTrials. gov NCT01656525 Available from: http://clinicaltrials.gov/ct2/show/NCT01656525?term=gantenerumab&rank=1 [Last accessed 10 June 2014]
75. Hoffmann-La Roche F. A study investigating the bioavailability of a high concentration liquid formulation versus a reference lyophilized formulation of gantenerumab in healthy volunteers. ClinicalTrials.gov NCT02133937 Available from: http://clinicaltrials.gov/ct2/show/NCT02133937?term=gantenerumab&rank= 2 [Last accessed 10 June 2014]
76. Villemagne VL, Pike KE, Chételat G, et al. Longitudinal assessment of Ab and cognition in aging and Alzheimer disease. Ann Neurol 2011;69:181-92
77. Moulder KL, Snider BJ, Mills SL, et al. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimers Res Ther 2013;5(5):48
78. Hoffmann-La Roche F. A study of gantenerumab in patients with prodromal Alzheimer's disease. ClinicalTrials.gov NCT01224106 Available from: http://clinicaltrials.gov/ct2/show/NCT01224106?term=NCT01224106&rank=1 [Last accessed 10 June 2014]
79. Hoffmann-La Roche F. A study of gantenerumab in patients with mild Alzheimer disease. ClinicalTrials.gov NCT02051608 Available from: http://clinicaltrials.gov/ct2/show/NCT02051608?term=gantenerumab&rank=3 [Last accessed 10 June 2014]
80. Weller RO, Subash M, Preston SD, et al. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol 2008; 18(2):253-66
81. Racke MM, Hepburn DL, Parsadainian M, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 2005;25(3):629-36
82. Das P, Loosbrock N, Dickson D, et al. Amyloid-(beta) immunization effectively reduces amyloid deposition in Fcr(gamma) (-/-) knock-out mice. J Neurosci 2003; 23(24):8532-8
83. Weller RO, Boche D, Nicoll JA. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. Acta Neuropathol 2009;118(1):87-102
84. Giuffrida ML, Caraci F, Pignataro B, et al. Beta-amyloid monomers are neuroprotective. J Neurosci 2009;29(34): 10582-7